Board of directors

Olivier joined the Andera Partners’ Life Sciences team based in Paris in 2006. Before that he worked with 3i in Venture Healthcare, first investing out of Munich, later out of Paris.

Prior to that, Olivier was a consultant with Mercer Management Consulting in Munich and Paris. Olivier holds a PhD in Biology from the Munich Institute für Genetik und Mikrobiology and has performed his scientific research in Munich and Oxford University.

Olivier is a Director of Allecra Therapeutics, JenaValve Technologies, MMI, Autonomic Technologies and MedLumics, and was a director of Novexel, Endosense, Sapiens and Probiodrug , SuperSonic Imagine and Noxxon Pharma up until their respective acquisitions or listings.

More than 12 years of experience in business development, technology transfer and in early stage investment. He is Director of the Life Science Invest Fund at Caixa Capital Risc and he serves on the Board of Directors at MedLumics, Aelix Therapeutics, Minoryx, iProteos, SpliceBio and Laboratoris Sanifit.

Pablo, gratuated in Chemistry from the University of Buenos Aires, holds a Ph.D. in Organic Chemistry from the University of Barcelona and a postdoc. Fulbright Fellow at the Department of System Biology at Hardvard University. Pablo has wide experience in technology transfer as Senior Innovation and Technology Transfer Manager at Botin Foundation and as a Director of the Technology and Business Development Office at the Center for Genome Regulation.

Giovanni Leo is a venture partner at Innogest Capital since 2017. Prior to Innogest he held the position of VP of RND at St Jude Medical since the acquisition of Endosense in 2013, which he co-founded to develop a novel technology for the catheter ablation treatment of cardiac arrhythmias.

Formerly he was the director of the Geneva offices for Acrostak Corp., a Boston-Scientific funded medical device company that developed the only European system for vascular brachytherapy. He was also co-founder of Isotopes and Metals Ltd., an emerging medical device company focused on technology for prostate and gynecological brachytherapy. Giovanni previously held a software quality manager position at LeCroy Corp.

Jim serves as Chief Executive Officer and a member of the Board of Directors for MedLumics bringing 30 years of extensive operational experience in medical device design, development, and commercialization.

Prior to joining MedLumics, Jim served as Partner in Seroba Life Sciences Limited, a Dublin based venture capital firm. Jim is a serial entrepreneur founding multiple medical device start-ups in the cardiovascular field serving as CEO of Verso Technologies, Inc., Apica Cardiovascular Ltd., Advanced Medical Technologies, Inc. (APK), and MitralSolutions, Inc. Earlier in his career, Jim held Director level positions at global medical device companies such as Medtronic, AVE, and Guidant.

Diego joined VI Partners in January 2003 as Partner focusing on Healthcare investments. He brings over 20 years of experience in life science, medical devices and pharmaceuticals in Europe and the US. Prior to his entry into the VC industry Diego has held various managerial positions in the pharmaceuticals and medical devices sectors, as well as in biotech start ups in Europe and the US.

Diego holds an M. Sc. in Microbiology from the Biocenter of the University of Basel and a Ph.D. in Molecular and Cellular Biology from the Swiss Cancer Research Institute (ISREC) in Lausanne,  he is fluent in English, French Italian and German and carries the prime responsibility for the following portfolio companies: Covalys, Edimer, Genkyotex, Merlion, Sequana and Xeltis.

Josep Ll. Sanfeliu is managing partner, president and co-founder at the venture capital firm ASABYS Partners (Barcelona). Formerly, he co-founded as Partner Ysios Capital (2008-2018) where he was the partner in charge of Health Technology investments. Previously Josep has worked in the pharmaceutical industry as Corporate Development Director at Almirall where he was involved with Business Development and in charge of M&A and corporate investments and also worked as General Manager leading operations in the segment of home-healthcare services at DomusVi . Josep started his career as a lawyer in Cuatrecasas and also worked in the financial sector in KPMG and Eurohold. His involvement in the entrepreneurial ecosystem has offered him the experience to support starting entrepreneurs in other sectors such as a the digital segment including Glovo, Vlex or 21buttons being one of the first early angel investors.

Dr. Peter Neubeck is a Medical Doctor, educated at Ludwig-Maximilians-Universität in Munich as well as Harvard Medical School and holds an MBA from INSEAD. After tenures at Gro ßhadern  University Clinic, Cleveland Clinic, and Beth Israel Deaconess Hospital followed by McKinsey & Company and several leadership positions at Novartis, he entered the Venture Capital industry. Hetook on responsibilities as an Investment Manager and collected valuable operational experience in various executive roles in company creations. Since January 2019 he heads the investment business of Kurma Partners in Germany .